Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
Abstract Background The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations. At the same time, severe COPD treatment, that often require a...
Main Authors: | Emanuela Resta, Giulia Scioscia, Donato Lacedonia, Carla Maria Irene Quarato, Francesco Panza, Onofrio Resta, Giorgia Lepore, Enrico Buonamico, Valentina Di Lecce, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro, Noemi Rossi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12913-022-08640-9 |
Similar Items
-
Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
by: Rothnie KJ, et al.
Published: (2022-06-01) -
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
by: Paly VF, et al.
Published: (2022-12-01) -
Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China
by: Ling Lin, et al.
Published: (2023-03-01) -
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
by: Bogart M, et al.
Published: (2024-01-01) -
Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
by: Serafeim-Chrysovalantis Kotoulas, et al.
Published: (2023-07-01)